SureSeq myPanel™ NGS Custom Cancer Panels enable researchers to create bespoke probe panels from an expert-curated library

Oxford, UK – Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its SureSeq myPanel™ NGS Custom Cancer Panels to provide scientists with completely customised, pre-optimised next generation sequencing (NGS) probe panels relevant to their research. The comprehensive library of gene content covers key cancer types including, myeloid, chronic lymphocytic leukaemia (CLL), ovarian and breast. Utilising hybridisation-based capture, the panels deliver unparalleled coverage completeness and uniformity, and are regularly updated for maximum relevance to current research. The panels provide uniform coverage through all target regions including intronic and splice sites and reduce the need for fill-in Sanger sequencing.

The pace of cancer and clinical genetics research means that fixed content NGS panels are unable to truly reflect the latest knowledge on gene